Table 3.

Proportion of patients experiencing a hemoglobin response at end of treatment and mean hemoglobin increase after 4 weeks of treatment by cohort

CohortResponders Overall (EOT), n (%)Mean (±SD) Hb Changes Overall, g/dlMean (±SD) Hb Changes by Category of Body Weight, g/dl
Lowest Tertile, ≤75.4 kgMiddle Tertile, 75.5–96.2 kgHighest Tertile, ≥96.3 kg
A (n=23)19 (82.6)a+1.71 (±0.21)+1.80 (±0.98)+1.72 (±1.10)+1.65 (±1.10)
B (n=24)24 (100)a+1.09 (±0.20)+0.92 (±0.72)+2.07 (±0.46)+0.72 (±1.10)
C (n=23)21 (91.3)b+0.57 (±0.21)+0.90 (±0.45)+0.40 (±0.62)+0.60 (±0.80)
D (n=24)23 (95.8)b+1.53 (±0.20)+2.49 (±0.84)+1.25 (±0.76)+0.78 (±0.39)
E (n=24)23 (95.8)b+0.77 (±0.20)+0.61 (±0.88)+0.95 (±0.83)+0.77 (±0.75)
F (n=25)21 (84.0)b+0.61 (±0.20)+1.13 (±0.92)+0.17 (±0.62)+0.35 (±0.53)
  • Hb, hemoglobin; EOT, end of treatment.

  • a EOT 16 weeks.

  • b EOT 24 weeks.